Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RDT-008
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RDT-008 is a fully human monoclonal antibody targeting CD70 (cluster of differentiation 70), a tumor-associated antigen overexpressed in clear cell renal cell carcinoma (ccRCC) and other solid tumors. Developed by the MD Anderson Cancer Center Therapeutics Discovery Division, RDT-008 is designed as an antibody-radionuclide conjugate (ARC) platform. It can be site-specifically radiolabeled with various isotopes, such as zirconium-89 (89Zr) for immuno-PET imaging, or lutetium-177 (177Lu) and terbium-161 (161Tb) for targeted radionuclide therapy. In preclinical models of ccRCC, RDT-008-based radiopharmaceuticals have demonstrated high target specificity, rapid internalization, and dose-dependent tumor growth inhibition, making it a promising theranostic candidate.
- Other names
- 161Tb-RDT-008177Lu-RDT-00889Zr-RDT-008[161Tb]Tb-RDT-008[177Lu]Lu-RDT-008[89Zr]Zr-RDT-008
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on RDT-008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RDT-008.